Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manjula Reddy

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Plos One|February 2, 2013
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone, Emily Woods, Susann M Szmania, et al.
British Journal of Haematology|November 7, 2017
Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disordersBrad Foulk, Mike Schaffer, Steve Gross, et al.
Nature Communications|November 16, 2017
Structural basis of adaptor-mediated protein degradation by the tail-specific PDZ-protease PrcMing-Yuan Su, Nilanjan Som, Chia-Yun Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
American Journal of Hematology|October 9, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Liana Gercheva, Cathy Williams, et al.
Blood|May 17, 2014
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myelomaJesús San-Miguel, Joan Bladé, Ofer Shpilberg, et al.
The Lancet. Oncology|July 22, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialFrits van Rhee, Raymond S Wong, Nikhil Munshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Plos One|February 2, 2013
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone, Emily Woods, Susann M Szmania, et al.
British Journal of Haematology|November 7, 2017
Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disordersBrad Foulk, Mike Schaffer, Steve Gross, et al.
Nature Communications|November 16, 2017
Structural basis of adaptor-mediated protein degradation by the tail-specific PDZ-protease PrcMing-Yuan Su, Nilanjan Som, Chia-Yun Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
American Journal of Hematology|October 9, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Liana Gercheva, Cathy Williams, et al.
Blood|May 17, 2014
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myelomaJesús San-Miguel, Joan Bladé, Ofer Shpilberg, et al.
The Lancet. Oncology|July 22, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialFrits van Rhee, Raymond S Wong, Nikhil Munshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
Pageof 5